Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Chinese Journal of Cancer Research
Metadata
Title
Relationship of PARG with PARP, VEGF and b-FGF in colorectal carcinoma
Authors
Ling Lin
Jia Li
Ya-lan Wang
Xiao Lin
Publication date
01-06-2009
Publisher
Chinese Anti-Cancer Association
Published in
Chinese Journal of Cancer Research / Issue 2/2009
Print ISSN: 1000-9604
Electronic ISSN: 1993-0631
DOI
https://doi.org/10.1007/s11670-009-0135-3

Other articles of this Issue 2/2009

Chinese Journal of Cancer Research 2/2009 Go to the issue

Gynecologic Cancer

Human papillomavirus 16E6 oncogene mutation in cervical cancer

Gastrointestinal Cancer

Relationship between VEGF, EGF and invasion, metastasis of gastric cancer cells

OriginalPaper

Effects of neuregulins on invasion and metastasis of non-overexpression ErbB2 breast cancer cells

Cellular and Molecular Biology

FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells

OriginalPaper

Comparative evaluation of the effects of 5-Aza-2’-deoxycytidine and Trichostatin A on reactivation of hMLH1 in COC1/DDP ovarian cancer cell line

Cancer Gene Therapy

An oncolytic adenovirus expressing herpes simplex virus-thymidine kinase for targeting cancer therapy: An in vitro evaluation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits